Literature DB >> 33570093

Hyperactive MEK1 Signaling in Cortical GABAergic Neurons Promotes Embryonic Parvalbumin Neuron Loss and Defects in Behavioral Inhibition.

Michael C Holter1, Lauren T Hewitt1,2, Kenji J Nishimura1,2, Sara J Knowles1, George R Bjorklund1, Shiv Shah1, Noah R Fry1, Katherina P Rees1, Tanya A Gupta3, Carter W Daniels3,4, Guohui Li5, Steven Marsh6, David Michael Treiman6, Michael Foster Olive3, Trent R Anderson5, Federico Sanabria3, William D Snider7, Jason M Newbern1.   

Abstract

Many developmental syndromes have been linked to genetic mutations that cause abnormal ERK/MAPK activity; however, the neuropathological effects of hyperactive signaling are not fully understood. Here, we examined whether hyperactivation of MEK1 modifies the development of GABAergic cortical interneurons (CINs), a heterogeneous population of inhibitory neurons necessary for cortical function. We show that GABAergic-neuron specific MEK1 hyperactivation in vivo leads to increased cleaved caspase-3 labeling in a subpopulation of immature neurons in the embryonic subpallial mantle zone. Adult mutants displayed a significant loss of parvalbumin (PV), but not somatostatin, expressing CINs and a reduction in perisomatic inhibitory synapses on excitatory neurons. Surviving mutant PV-CINs maintained a typical fast-spiking phenotype but showed signs of decreased intrinsic excitability that coincided with an increased risk of seizure-like phenotypes. In contrast to other mouse models of PV-CIN loss, we discovered a robust increase in the accumulation of perineuronal nets, an extracellular structure thought to restrict plasticity. Indeed, we found that mutants exhibited a significant impairment in the acquisition of behavioral response inhibition capacity. Overall, our data suggest PV-CIN development is particularly sensitive to hyperactive MEK1 signaling, which may underlie certain neurological deficits frequently observed in ERK/MAPK-linked syndromes.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Entities:  

Keywords:  ADHD; ERK1/2; RASopathy; development; ganglionic eminence

Mesh:

Substances:

Year:  2021        PMID: 33570093      PMCID: PMC8325019          DOI: 10.1093/cercor/bhaa413

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  110 in total

1.  Rapid developmental maturation of neocortical FS cell intrinsic excitability.

Authors:  Ethan M Goldberg; Hyo-Young Jeong; Ilya Kruglikov; Robin Tremblay; Roman M Lazarenko; Bernardo Rudy
Journal:  Cereb Cortex       Date:  2010-08-12       Impact factor: 5.357

2.  ERK/MAPK Signaling Is Required for Pathway-Specific Striatal Motor Functions.

Authors:  Scott R Hutton; James M Otis; Erin M Kim; Yashna Lamsal; Garret D Stuber; William D Snider
Journal:  J Neurosci       Date:  2017-07-21       Impact factor: 6.167

3.  Energy deficit in parvalbumin neurons leads to circuit dysfunction, impaired sensory gating and social disability.

Authors:  Melis Inan; Mingrui Zhao; Monica Manuszak; Cansu Karakaya; Anjali M Rajadhyaksha; Virginia M Pickel; Theodore H Schwartz; Peter A Goldstein; Giovanni Manfredi
Journal:  Neurobiol Dis       Date:  2016-04-20       Impact factor: 5.996

Review 4.  Casting a Wide Net: Role of Perineuronal Nets in Neural Plasticity.

Authors:  Barbara A Sorg; Sabina Berretta; Jordan M Blacktop; James W Fawcett; Hiroshi Kitagawa; Jessica C F Kwok; Marta Miquel
Journal:  J Neurosci       Date:  2016-11-09       Impact factor: 6.167

5.  Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling.

Authors:  Pietro Fazzari; Ana V Paternain; Manuel Valiente; Ramón Pla; Rafael Luján; Kent Lloyd; Juan Lerma; Oscar Marín; Beatriz Rico
Journal:  Nature       Date:  2010-04-14       Impact factor: 49.962

6.  Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study.

Authors:  Shruti Garg; Annukka Lehtonen; Susan M Huson; Richard Emsley; Dorothy Trump; D Gareth Evans; Jonathan Green
Journal:  Dev Med Child Neurol       Date:  2012-11-16       Impact factor: 5.449

7.  Origin and route of tangentially migrating neurons in the developing neocortical intermediate zone.

Authors:  N Tamamaki; K E Fujimori; R Takauji
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

8.  Sustained activation of ERK1/2 MAPK in oligodendrocytes and schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion.

Authors:  Akihiro Ishii; Miki Furusho; Rashmi Bansal
Journal:  J Neurosci       Date:  2013-01-02       Impact factor: 6.167

9.  Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.

Authors:  Corina Anastasaki; David H Gutmann
Journal:  Hum Mol Genet       Date:  2014-07-28       Impact factor: 6.150

10.  Perineuronal nets decrease membrane capacitance of peritumoral fast spiking interneurons in a model of epilepsy.

Authors:  Bhanu P Tewari; Lata Chaunsali; Susan L Campbell; Dipan C Patel; Adam E Goode; Harald Sontheimer
Journal:  Nat Commun       Date:  2018-11-09       Impact factor: 14.919

View more
  3 in total

1.  Chromatin remodeller CHD7 is required for GABAergic neuron development by promoting PAQR3 expression.

Authors:  Priyanka Jamadagni; Maximilian Breuer; Kathrin Schmeisser; Tatiana Cardinal; Betelhem Kassa; J Alex Parker; Nicolas Pilon; Eric Samarut; Shunmoogum A Patten
Journal:  EMBO Rep       Date:  2021-04-26       Impact factor: 8.807

Review 2.  Translating the Role of mTOR- and RAS-Associated Signalopathies in Autism Spectrum Disorder: Models, Mechanisms and Treatment.

Authors:  Verica Vasic; Mattson S O Jones; Denise Haslinger; Lisa S Knaus; Michael J Schmeisser; Gaia Novarino; Andreas G Chiocchetti
Journal:  Genes (Basel)       Date:  2021-10-30       Impact factor: 4.141

3.  The Impact of Maternal Antioxidants on Prenatal Stress Effects on Offspring Neurobiology and Behavior.

Authors:  Jada L-B Davis; Mara O'Connor; Hannah Erlbacher; Sarah L Schlichte; Hanna E Stevens
Journal:  Yale J Biol Med       Date:  2022-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.